Cargando…

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting

Detalles Bibliográficos
Autor principal:	Takeda, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475551/ https://www.ncbi.nlm.nih.gov/pubmed/32944373 http://dx.doi.org/10.21037/jtd-2020-46

Ejemplares similares

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer
por: Nakao, Masayuki, et al.
Publicado: (2020)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Surgical treatment of small-sized non-small cell lung cancer—a dilemma for surgeons
por: Kodama, Ken, et al.
Publicado: (2020)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
por: Cortellini, Alessio, et al.
Publicado: (2020)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy
por: Nagl, Laurenz, et al.
Publicado: (2023)

Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
por: Kauffmann-Guerrero, Diego
Publicado: (2020)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Advancing Transition in Resource-Constrained Settings
por: Sinnappurajar, Praisoody, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
por: Safyan, Rachael A., et al.
Publicado: (2018)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Adjuvant EGFR-TKIs-based therapy: are we ready?
por: Tam, Terence
Publicado: (2020)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Adjuvant chemotherapy for locally advanced non-small cell lung cancer: still state of the art or an outdated therapy?
por: Schlachtenberger, Georg, et al.
Publicado: (2023)

Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?
por: Rastogi, Sameer, et al.
Publicado: (2017)

Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2020)

In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
por: Bindal, Poorva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i7nvpjkqtar5ui15g5n3iegecj